|POZEN Announces Upcoming Presentations at the American Headache Society's 45th Annual Scientific Meeting|
CHAPEL HILL, N.C.--(BUSINESS WIRE)--June 16, 2003--POZEN Inc. (NASDAQ: POZN) a pharmaceutical company developing therapeutic advancements in a cost effective manner, today announced it will be presenting information from three abstracts at the 45th Annual Scientific Meeting of The American Headache Society (AHS). The meeting will be held from Thursday, June 19, through Sunday, June 22, 2003 at The Fairmont Chicago hotel.POZEN abstracts to be presented at the AHS annual meeting are:
Title: Defining and Analyzing Meaningful Relief in Clinical Trials
of Acute Migraine Headache
Title: A New Formulation of Dihydroergotamine (DHE) is Effective
for Sustaining Relief in the Acute Treatment of Migraine
Title: Barriers to the Use of Oral Triptans by Patients Diagnosed
with Migraine Headaches
The clinical data to be presented include results from two Phase III studies for MT 300, the company's injectable product candidate designed to provide significant and long-lasting pain relief for patients seeking a convenient, well tolerated injectable therapy. Top line results from the studies were announced by POZEN in press releases issued on July 22, 2002 and October 4, 2002.
POZEN is a pharmaceutical company developing therapeutic advancements in a cost effective manner. Since its inception, POZEN has developed the largest and most advanced product pipeline in the field of migraine. Product development efforts are focused on diseases with unmet medical needs where POZEN can improve efficacy, safety, and/or patient convenience. POZEN recently signed a development and commercialization agreement with GlaxoSmithKline for a novel migraine treatment. The company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN." For detailed company information, see POZEN's website: www.pozen.com.
POZEN forward-looking statements: Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and FDA approval of our product candidates, resulting in, among other things, our failure to achieve milestones that would have provided us with revenue; our inability to enter into or maintain, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events, including those discussed herein and in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2003 under "Management's Discussion and Analysis of Financial Condition and Results of Operations." We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.